Collectively, this study suggests that harnessing inhibitors of SCD1 and FADS2 to selectively remove ascites-derived cancer cells could be a promising chemotherapeutic regimen to eradicate peritoneal metastases of OvCa and exhibited no cytotoxicity in normal cells and in vivo. This evidence concerns the gene FADS2 and cancer.